Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model

Journal of Infectious Diseases

Volumn 179, Issue SUPPL. 1, 1999, Pages

  Huggins, John ^a   Zhang, Zhen Xi ^a,b   Bray, Mike ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Acambis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSYLHOMOCYSTEINASE INHIBITOR; RIBAVIRIN; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIVIRAL ACTIVITY; CONFERENCE PAPER; EBOLA VIRUS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FILOVIRIDAE; GUINEA PIG; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS PLAQUE; VIRUS REPLICATION;

EID: 0033026484     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514316     Document Type: Conference Paper

References (21)

1. 1. Piot P, Sureau P, Bremen G, et al. Clinical aspects of Ebola virus infection in Yambuku area, Zaire, 1976. In: Pattyn SR, ed. Ebola virus haemorrhagic fever. Amsterdam: Elsevier/North-Holland Biomedical Press, 1978:7-14.
2. 2. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989; 11: S750-61.
3. 3. Jahrling PB, Geisbert J, Swearengen JR, et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl 1996; 11:135-40.
4. 4. Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. Br Med J 1977;2:541-4.
5. 5. Sanchez A, Kiley MP, Holloway BP, McCormick JB, Auperin DD. The nucleoprotein gene of Ebola virus: cloning, sequencing, and in vitro expression. Virology 1989; 170:81-91.
6. 6. Huggins JW, Zhang Z, Monath TI. Inhibition of Ebola virus replication in vitro and in a SCID mouse model by S-adenosylhomocysteine hydrolase inhibitors [abstract]. Antiviral Res 1991(suppl 1):122.
7. 7. De Clercq E, Montgomery JA. Broad-spectrum antiviral activity of the carbocyclic analog of 3-deazaadenosine. Antiviral Res 1983;3:17-24.
8. 8. DC Clercq E. S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem Pharmacol 1987;36:2567-75.
9. 9. Geisbert TW, Jahrling PB. Differentiation of filoviruses by electron microscopy. Virus Res 1995;39:129-150.
10. 10. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998;178:651-61 and 1999; 179(suppl 1):S248-58.
11. 10. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998;178:651-61 and 1999; 179(suppl 1):S248-58.
12. 11. Montgomery JA, Clayton SJ, Thomas HJ, et al. Carbocyclic analogue of 3-deazaadenosine: a novel antiviral agent using S-adenosylhomocysteine hydrolase as a pharmacological target. J Med Chem 1982;25:626-9.
13. 12. Moe JB, Lambert RD, Lupton HW. Plaque, assay for Ebola virus. J Clin Microbiol 1981; 13:791-3.
14. 13. Gabrielsen B, Monath TP, Huggins JW, et al. Antiviral (RNA) activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related substances, J Nat Prod 1992;55:1569-81.
15. 14. Horling J, Lundkvist A, Huggins J, Niklasson B. Antibodies to Puumala virus in humans determined by neutralization test. J Virol Methods 1992; 39:139-47.
16. 15. Kirsi JJ, North JA, Mckernan PA, et al. Broad-spectrum antiviral activity of 2-β-D-ribofuranosyl selenazole 4 carboxamide, a new antiviral agent. Antimicrob Agents Chemother 1983;24:353-61.
17. 16. Huggins JW. RNA viruses that cause hemorrhagic, encephalitic, and febrile disease. In: Galasso GJ, Whitley RJ, Merigan TC, eds. Antiviral agents and viral diseases of man. New York: Raven Press, 1990:691-726.
18. 17. Coulombe RA Jr, Huie JM, Sharma RP, Huggins JW. Pharmacokinetics of the antiviral agent carbocyclic 3-deazaadenosine. Drug Metab Dispos 1993;21:555-9.
19. 18. Coulombe RA Jr, Sharma RP, Huggins JW, Pharmacokinetics of the antiviral agent 3-deazaneplanocin A, Eur J Drug Metab Pharmacokinet 1995, 20:197-202.
20. 19. Guranowski A, Montgomery JA, Cantoni GL, Chiang PK. Adenosine analogues as substrates and inhibitors of S-adenosylhomocysteine hydrolase. Biochemistry 1981;20:110-5.
21. 20. Wyde PR, Ambrose MW, Meyer HL, Zolinski CL, Gilbert BE. Evaluation of the toxicity and antiviral activity of carbocyclic 3-deazaadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral Res 1990; 14:215-25.